Skip to main content
رجوع
BNTX logo

BioNTech SE

جودة البيانات: 100%
BNTX
NASDAQ Healthcare Biotechnology
KWD 88.41
▼ KWD 0.86 (-0.96%)
القيمة السوقية: 22.22B
نطاق اليوم
KWD 87.99 KWD 90.94
نطاق 52 أسبوعًا
KWD 79.52 KWD 124.00
حجم التداول
1,191,903
متوسط 50 يوم / 200 يوم
KWD 105.31 / KWD 104.33
الإغلاق السابق
KWD 89.27

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -20.4 0.4
P/B 1.2 2.9
ROE % -5.7 3.8
Net Margin % -39.6 3.9
Rev Growth 5Y % -38.3 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 137.380 +55.4%
Low: KWD 113.000 High: KWD 155.000
ربحية السهم المستقبلية
-KWD 4.336
الإيرادات المقدّرة
2.3 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 0.065
-KWD 0.085 – -KWD 0.050
3.7 B 3
FY2029 -KWD 2.476
-KWD 3.237 – -KWD 1.903
2.9 B 3
FY2028 -KWD 3.237
-KWD 9.145 – -KWD 0.731
2.8 B 9

النقاط الرئيسية

Revenue declined -38.26% annually over 5 years
Debt/Equity of 0.01 — conservative balance sheet
Generating 269.81M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 38.46%
Capital efficient — spends only 6.10% of revenue on capex

النمو

Revenue Growth (5Y)
-38.26%
Revenue (1Y)0.20%
Earnings (1Y)N/A
FCF Growth (3Y)-75.95%

الجودة

Return on Equity
-5.65%
ROIC-2.40%
Net Margin-39.59%
Op. Margin-22.63%

الأمان

Debt / Equity
0.01
Current Ratio7.54
Interest Coverage-45.74

التقييم

P/E Ratio
-20.36
P/B Ratio1.16
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.20% Revenue Growth (3Y) -15.04%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -38.26% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.76B Net Income (TTM) -1.09B
ROE -5.65% ROA -4.96%
Gross Margin 77.64% Operating Margin -22.63%
Net Margin -39.59% Free Cash Flow (TTM) 269.81M
ROIC -2.40% FCF Growth (3Y) -75.95%
Safety
Debt / Equity 0.01 Current Ratio 7.54
Interest Coverage -45.74 Dividend Yield 0.00%
Valuation
P/E Ratio -20.36 P/B Ratio 1.16
P/S Ratio 8.06 PEG Ratio -0.29
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 22.22B Enterprise Value 14.81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.76B 2.75B 3.82B 17.31B 18.98B
Net Income -1.09B -665.30M 930.30M 9.43B 10.29B
EPS (Diluted) -4.51 -2.77 3.83 37.09 41.21
Gross Profit 2.14B 2.21B 3.22B 14.32B 16.07B
Operating Income -623.87M -1.31B 690.40M 12.64B 15.28B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 21.98B 22.53B 23.01B 23.28B 15.83B
Total Liabilities 2.76B 3.12B 2.76B 3.22B 3.94B
Shareholders' Equity 19.22B 19.41B 20.25B 20.06B 11.89B
Total Debt 267.29M 254.20M 219.10M 212.20M 301.50M
Cash & Equivalents 7.67B 9.76B 11.66B 13.88B 1.69B
Current Assets 16.14B 18.80B 19.53B 21.92B 15.07B
Current Liabilities 2.14B 2.52B 2.07B 2.95B 3.48B